A promising best-in-class rare disease treatment
AATD is an inherited rare disease of the lungs and liver, which according to
INBRX-101 is a recombinant human AAT-Fc fusion protein under development for the treatment of AATD. The therapy has potential to enable these patients attain normal serum AAT levels via monthly rather than weekly dosing.
By inhibiting neutrophil elastase, an enzyme responsible for lung tissue damage, INBRX-101 could help lower inflammation and prevent further decline in lung function in AATD patients,
INBRX-101 could offer a significant improvement in the treatment options and quality of life for patients with [alpha-1 antitrypsin deficiency] AATD”
In a Phase I clinical trial, INBRX-101 demonstrated positive results in terms of safety and pharmacokinetics.
A Phase II trial evaluating INBRX-101 is currently in the enrolment stage. If successful, INBRX-101 could offer a significant improvement in the treatment options and quality of life for patients with AATD,
Further details of the transaction
"The addition of INBRX-101 as a high potential asset to our rare disease portfolio… [means that the treatment will help to] address the needs of the underserved AATD patients and communities,"
This agreement follows
In
The post
© Russell Publishing Limited, 2024. All Rights Reserved., source